Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Profiling bladder cancer using targeted antibody arrays.

Marta Sanchez-Carbayo1, Nicholas D Socci, Juan Jose Lozano

  • 1Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. Marta.Sanchez-Carbayo@cnio.es

The American Journal of Pathology
|January 10, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer's disease.

Nature communications·2026
Same author

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Cancer discovery·2026
Same author

Author Correction: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Nature genetics·2026
Same author

Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV.

Vaccine·2025
Same author

Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Nature genetics·2025
Same author

An improved and economical LLE-LC/MS method for quantifying phosphatidylethanol: Identification and separation of isotopic cross-talk in clinical alcohol testing.

Clinical biochemistry·2025

This study developed antibody arrays to detect bladder cancer biomarkers in blood. These protein profiles accurately identified bladder cancer and predicted patient survival, aiding early diagnosis and treatment.

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Proteomics

Background:

  • Bladder cancer necessitates vigilant surveillance due to high recurrence rates and poor outcomes in invasive stages.
  • Current serum biomarkers for bladder cancer lack the required sensitivity and specificity for effective diagnosis and staging.
  • Identifying novel, reliable biomarkers is crucial for improving bladder cancer management.

Purpose of the Study:

  • To develop and validate antibody arrays for identifying bladder cancer patients using serum protein profiles.
  • To assess the capability of serum protein profiles in predicting overall survival for bladder cancer patients.
  • To correlate specific serum protein biomarkers with clinical parameters like pathological stage and tumor grade.

Main Methods:

  • Designed antibody arrays targeting proteins differentially expressed in bladder tumors.

Related Experiment Videos

  • Analyzed serum protein profiles from bladder cancer patients and controls using a 254-antibody array.
  • Validated findings with a 144-antibody array and immunohistochemistry on tissue microarrays (n=173).

    • Main Results:

    • A 254-antibody array correctly classified bladder cancer patients from controls with 93.7% accuracy.
    • A 144-antibody array demonstrated that protein profiles could stratify patients by overall survival (P=0.0479).
    • Key proteins, like c-met, correlated with pathological stage, tumor grade, and survival outcomes.

    Conclusions:

    • Serum protein profiles analyzed by antibody arrays offer a promising approach for bladder cancer diagnosis.
    • These profiles can stratify patients based on clinical outcome, potentially guiding therapeutic interventions.
    • Integrated biomarker discovery technologies strengthen diagnostic and prognostic capabilities for bladder cancer.